UCB's Epilepsy Drug Patent Win Upheld By Fed. Circ.
The Federal Circuit on Wednesday affirmed a Delaware federal court's finding that a UCB Inc. patent on the epilepsy drug Vimpat is not invalid for double patenting or obviousness, upholding the...To view the full article, register now.
Already a subscriber? Click here to view full article